Strong Revenue Growth
Total revenue for Q3 2024 was $58.4 million, representing a 66% increase compared to Q3 2023. U.S. revenue grew by 62% while international revenue increased by 121%.
Successful Launch of HYDROS Robotic System
HYDROS system accounted for 80% of the 45 robotic systems sold in Q3. The launch has been met with positive feedback for its AI assist feature and streamlined setup process.
Record Gross Margin
Achieved an all-time high gross margin of 63.2% due to higher HYDROS system average selling prices.
FDA Breakthrough Device Designation
The FDA granted breakthrough device designation for a clinical trial of Aquablation therapy for prostate cancer, representing a significant milestone.
Positive Utilization Trends
U.S. handpiece and consumable revenue grew by 74% with a 79% increase in handpiece units, driven by an expanded installed base and increased utilization per account.